Interesting graphical retracement for the Amgen stock which sees a considerable decline from the highs of the year. Where does the caution stem from? First, management highlighted that new patient prescriptions remain below pre-COVID-19 levels, and second, variants are suggesting demand may be muted for now. The stock has a solid capital appreciation potential and dividend growth prospects out to 2024-2026.
Annual Profit: 9.5 bil $
Total debt: 32.7 bil $
Annual Profit: 9.5 bil $
Total debt: 32.7 bil $